Company: HQL
Filing Date: 2025-12-08
Form Type: N-CSR
Source: 0001104659-25-119341
Chunk: 36

Company: abrdn Life Sciences Investors
Filing Date: 2025-12-08
Form: N-CSR
Chunk 36
---
 of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Such procedures also included confirmation of securities owned as of September 30, 2025, by correspondence with the custodian, respective portfolio company, and brokers; when replies were not received from brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion. We have served as the auditor of one or more abrdn investment companies since 2009. Columbus, Ohio
November 28, 2025

| abrdn Life Sciences Investors | 33 |

Federal Tax Information: Dividends and Distributions (Unaudited) Designation Requirements Of the distributions paid by the Fund from ordinary income for the year ended September 30, 2025, the following percentages met the requirements to be treated as qualifying for the corporate dividends received deduction and qualified dividend income, respectively. Dividends Received Deduction 2.44% Qualified Dividend Income 2.61% $2,790,714 from long-term capital gains, subject to a long-term capital gains tax rate of not greater than 20%.. The above amounts are based on the best available information at this time. In early 2026, the Fund will notify applicable shareholders of final amounts for use in preparing 2025 U.S. federal income tax forms.

| 34 | abrdn Life Sciences Investors |

Supplemental Information (Unaudited) Results of Annual Meeting of Shareholders The Annual Meeting of Shareholders was held on May 28, 2025. The description of each proposal and number of shares voted at the meeting are as follows: To elect two Class C Trustees to the Board of Trustees:

|                |  Votes For | Votes Against/ 
       Withheld |
| Rose DiMartino | 16,018,555 |      3,906,874 |
| Todd Reit      | 16,041,001 |      3,884,428 |

Summary of Board Considerations in Approving the Investment Advisory Agreement At a regularly scheduled meeting (the